Home / Clinical Decision Support & Reference / Neuroreader

Neuroreader

by Brainreader · Based in Denmark → — Automated Brain Volumetric Analysis From Routine MRI

Neurology Neurosurgery Radiology

Website

Claim this tool

Is this the maker? Claim the company →

Leave this field empty

Correct company / maker

Company website (optional)

Anything else? (optional)

Customized solutions that range from pay per use to multi-year subscriptions.

Regulatory Status Disclosed

Overview

Neuroreader is an FDA-cleared, CE-marked AI-enabled brain volumetric analysis tool that quantifies 83 brain regions from routine MRI to enhance diagnostic precision for neurodegenerative disorders. It automatically analyzes MRI scans and generates a quantitative volumetric brain report in under 10 minutes. By precisely measuring brain structure and identifying patterns of atrophy, Neuroreader helps clinicians better understand brain health over time, supporting earlier insight, improved differentiation, and confident clinical decision-making. Neuroreader converts standard brain MRI scans into objective brain volume measurements, helping clinicians assess brain structure more consistently and efficiently. It post-processes a 3D T1-weighted MRI, segments brain structures, measures their volumes, and compares results to a validated normative database adjusted for age, sex, and head size.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

Automated brain volumetric analysis
Quantifies 83 brain regions
Generates reports in under 10 minutes
Compares to normative database (age, sex, head size adjusted)
Longitudinal tracking of brain volume changes
Asymmetry analysis for TBI (13 structures)
PACS integration
Secure web portal access
Customizable reports
Brain heat maps visualization

Use Cases

Early diagnosis of neurodegenerative conditions
Monitoring disease progression
Differentiating neurological conditions
Supporting treatment planning
Assessing traumatic brain injury (TBI)
General brain health assessment

What Physicians Need to Know

Evidence Base (guidelines, literature scope)

Neuroreader is supported by a growing body of peer-reviewed research and independent validation studies. It is FDA-cleared and CE-marked medical software. The normative database used for comparisons is derived from MRI scans of healthy individuals, adjusted for age, sex, and head size. The software quantifies 83 brain structures and compares them to this validated normative database.

Clinical Validation Studies

Neuroreader has been independently validated in peer-reviewed research and clinical practice. Studies have demonstrated its accuracy and clinical utility in neurological diseases such as Alzheimer's dementia, traumatic brain injury (TBI), and mesial temporal sclerosis. It has been tested for detecting mesial temporal sclerosis in epilepsy patients and for dementia diagnosis in memory clinic cohorts. One study showed a Dice Similarity Coefficient (DSC) of 0.87 for hippocampal segmentation when compared to gold standard manual segmentation.

Alert Fatigue Management

The provided information does not specifically detail features for alert fatigue management within Neuroreader. However, it aims to provide objective, quantitative data to supplement visual MRI interpretation, which could potentially reduce ambiguity and the need for excessive alerts.

Differential Diagnosis Support

Neuroreader aids in differential diagnosis by providing objective brain volume measurements and identifying atrophy patterns. It helps distinguish Alzheimer's disease from conditions like depression, vascular dementia, and traumatic brain injury by quantifying subtle changes across multiple brain regions and comparing them to normative data. Case studies highlight its use in differentiating Alzheimer's dementia from frontotemporal dementia and TBI.

Guideline Update Frequency

The frequency of guideline updates for Neuroreader is not explicitly stated. However, the company emphasizes its support by a growing body of peer-reviewed research and independent validation studies, suggesting ongoing scientific engagement.

Clinical Workflow Integration

Neuroreader is designed for seamless integration into existing clinical workflows. It integrates via secure web access, PACS integration, on-site mediation servers, or AI marketplaces. Reports can be returned directly to PACS and zero-footprint viewers. The analysis occurs after a standard 3D T1-weighted MRI is completed and typically generates a report in less than 10 minutes.

Decision Audit Trail

The provided information does not specifically detail a decision audit trail feature within Neuroreader itself. However, EMR systems generally include audit trails that record all actions taken on a patient's electronic medical record, which would encompass the use and interpretation of tools like Neuroreader.

Physician Tip

Neuroreader provides quantitative, objective brain volume measurements that can supplement visual MRI interpretation, aiding in earlier detection, improved differentiation of neurological conditions (e.g., Alzheimer's vs. TBI), and monitoring disease progression over time. It can help identify subtle structural changes not always apparent to the human eye. Remember that Neuroreader is a clinical decision support tool and its reports should be interpreted by a qualified physician within the broader clinical context.

Neuroreader offers flexible integration options including direct PACS integration, secure web portal access, and on-site mediation servers, or through AI marketplaces. It is compatible with major MRI scanner brands (Siemens, GE, Philips) and utilizes standard 3D T1 sequences. Reports can be delivered electronically to PACS, web portals, or integrated clinical systems.

At a glance

Pricing Customized solutions that range from pay per use to multi-year subscriptions.

Deployment Cloud Based; On Premise (mediation Server); PACS Integration; AI Marketplaces

Visit site

Details

Category	Clinical Decision Support & Reference, Neurology AI, Radiology & Imaging AI
Pricing	Customized solutions that range from pay per use to multi-year subscriptions. — Customized solutions; Pay-per-use; Multi-year subscriptions
Deployment	Cloud-based; On-premise (mediation server); PACS integration; AI marketplaces
Compliance
BAA Available	Unknown AI-estimated
HIPAA Compliant	Unknown AI-estimated
FDA Status	1 AI-estimated Neuroreader is FDA-cleared (Class II) and CE-marked. It received FDA clearance in 2015.
Integrations
EHR	Not specified
Specialties	Neurology, Neurosurgery, Radiology

What the Web Says

Neuroreader is an FDA-cleared and CE-marked medical software that analyzes brain MRI scans to provide quantitative volumetric reports. It aims to offer more precise insights into brain health than visual interpretation alone, assisting physicians in the early detection and monitoring of neurodegenerative diseases like Alzheimer's, epilepsy, depression, and traumatic brain injury. The software processes MRI scans and generates a detailed report in less than 10 minutes, significantly reducing the time traditionally required for manual analysis.

Overall: Positive

Strengths

Faster analysis: Reduces MRI reading time from approximately 24-30 minutes to under 10 minutes.
High accuracy: Shown to be over 87% accurate compared to the 'gold standard' manual segmentation.
Early detection: Helps physicians identify subtle changes in brain structure earlier, potentially years before symptoms become noticeable.
Quantitative and reproducible measurements: Provides objective data, reducing uncertainty and variability in interpretation among clinicians.
Supports treatment planning and monitoring: Aids in creating treatment plans and tracking changes and progression of neurological conditions over time.
FDA-cleared and CE-marked: Indicates regulatory approval for medical use.

Limitations

Limited public reviews: Most available information comes from company-published studies and articles, with a lack of independent user reviews from platforms like G2, Capterra, or Reddit directly pertaining to Neuroreader (Brainreader).
Potential for misinterpretation: While a clinical support tool, it is not a diagnosis on its own and requires physician interpretation alongside other evaluations.
Availability may vary: Access to Neuroreader analysis may depend on the hospital or imaging center.
Focus on specific conditions: Primarily highlighted for neurodegenerative diseases and traumatic brain injury, though it measures 45 brain structures.

Based on reviews from: Research study validates neuroreader for accurate and fast measurement of brain volumes, Neuroreader Software Speeds Detection of Brain Volume Changes, Brainreader's Neuroreader software quickly detects changes in brain volume via MR, What is Neuroreader? & How to Request It - BrainReader, Neuroreaderu00ae Brain Volumetric Report Reduces MRI Diagnosis Time - BrainReader, Neuroreaderu00ae | Frequently Asked Questions - BrainReader, Neuroreader | Case Studies - BrainReader, Mind-reading AI works out what you are thinking from brain scans : r/technology - Reddit, Neurored TMS & SCM Software Reviews 2026. Verified Reviews, Pros & Cons | Capterra, Neuro Software Pricing, Alternatives & More 2026 - Capterra, Neurored TMS & SCM Software Reviews 2026: Details, Pricing, & Features | G2, A question about neuroradiology : r/neurology - Reddit, Neurored Products | Read 26 Reviews on G2, Brainreader raises u20ac6.6M to expand AI-driven neurological diagnostic platform - Tech.eu, neurology vs neuroradiology : r/medicalschool - Reddit, Best Neurodiversity Cognitive Assessment Software: User Reviews from June 2026 - G2, Capterra Reviews & Ratings 2026 - TrustRadius, Best Neurology EMR Software 2026 | Capterra, NeuronWriter Software Pricing, Alternatives & More 2026 | Capterra, NeuroAtHome Reviews 2026: Details, Pricing, & Features - G2, What should I expect from an MRI of my brain? : r/Explainlikeimscared - Reddit, Scientists developed an AI model that can interpret and diagnose a brain MRI within seconds, with up to 97.5% accuracy and can predict the urgency of a patient's required treatment : r/technology - Reddit, Greenlight Guru Clinical Reviews 2026: Details, Pricing, & Features | G2, 20 Best Neuroradiologists Near Sarasota, FL - Healthgrades

Last updated: 2026-06-21

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Neuroreader

Clinical Value

Ease of Use

Integration

Support & Docs

Value for Money

Your Name *

Email *

Your Role

Specialty

Your Review * (min 50 characters)

Press & Coverage

Dahlgren Capital

Dahlgren Capital Leads u20ac6.6M Investment in Danish Medtech Innovator Brainreader

Dahlgren Capital led a u20ac6.6 million investment in Brainreader, the Danish medtech company behind Neuroreader, to accelerate its global expansion, particularly in the U.S. healthcare market, and support further development of its AI-powered diagnostic solutions. Neuroreader is CE-marked and FDA-cleared software that provides fast, precise volumetric analysis of brain MRI scans to aid in diagnosing neurological conditions.

2025-05

Tech.eu

Brainreader raises u20ac6.6M to expand AI-driven neurological diagnostic platform - Tech.eu

Danish medtech company Brainreader secured u20ac6.6 million in funding to accelerate the global rollout of its AI-driven diagnostic platform, Neuroreader, which is a CE-marked and FDA-cleared software for automated volumetric analysis of brain MRI scans. The investment, led by Dahlgren Capital, will support commercial expansion in the U.S. and continued development of new features.

2025-05

ArcticStartup

Danish startup attracts $7.3M to develop clinical applications and broaden market reach - ArcticStartup

Brainreader, an Aalborg-based medtech company, raised $7.3 million in new funding, led by Dahlgren Capital, to support the global rollout of its AI-powered brain diagnostics software, Neuroreader. The funding will be used to expand its commercial presence, particularly in the U.S., and further develop the platform's clinical capabilities for diagnosing neurological conditions.

2025-05

Radiology Business

Brainreader appoints leading neuroradiologist and world-class physician-scientist Cyrus A. Raji, MD, PhD as chief medical officer - Radiology Business

Brainreader, the developer of Neuroreader, announced the appointment of Cyrus A. Raji, MD, PhD, a tenured associate professor of radiology and neurology, as its new consulting Chief Medical Officer. Dr. Raji's expertise in quantitative MRI and neurodegeneration will strengthen Brainreader's clinical leadership and accelerate innovation in volumetric imaging.

2026-01

FDA

Class 2 Device Recall Neuroreader Medical Image Processing Software

The FDA issued a Class 2 Device Recall for Neuroreader Medical Image Processing Software due to a discrepancy in the reference normative database distributed with the software compared to the version reviewed and cleared by the FDA. The software was upgraded to Version 2.5 to correct this issue.

2026-06

Brainreader

New Study Highlights Diagnostic Power of Neuroreader in Alzheimer's

A BMC Neurology study demonstrated that MRI volumetry, utilizing Neuroreader, can accurately differentiate major neurocognitive disorders by identifying distinct patterns of brain volume loss. This highlights Neuroreader's diagnostic power in conditions like Alzheimer's.

2024-09

Neurology

Diagnostic Utility of Volumetric Brain MRI Quantification for Distinguishing Frontotemporal Dementia from Alzheimeru2019s Disease (2554)

A study published in Neurology found that clinically available, quantitative volumetric MR neuroimaging combined with a predictive analytic approach using Neuroreader volumes can distinguish behavioral variant Frontotemporal Dementia (bvFTD) from Alzheimer's Disease (AD) with high accuracy, sensitivity, and specificity.

2020-04

PubMed

Memory Performance and Quantitative Neuroimaging Software in Mild Cognitive Impairment: A Concurrent Validity Study - PubMed

This study, published in the Journal of the International Neuropsychological Society, supported the use of MR Neuroreader hippocampal volumes as a clinically informative biomarker associated with memory performance, a critical diagnostic feature of Mild Cognitive Impairment (MCI). It found that evaluating memory performance across multiple measures better predicted hippocampal volume than individual performances.

2020-11

Videos

Product demos, reviews, and walkthroughs for Neuroreader.

Brainreader - cutting edge medical technology for everyone

Brainreader

Neuroreader Patient Case 1: Alzheimer's Dementia

Brainreader Inc.

Daily Medtech News with Smarteeva - 28 May

Smarteeva Software

View all on YouTube

Frequently Asked Questions

How does Neuroreader integrate into my existing clinical workflow for patient assessment?

Neuroreader analyzes MRI scans to provide quantitative volumetric data of brain structures, aiding in the assessment of neurodegenerative diseases. The results are presented in a clear report that can be easily incorporated into your patient's electronic health record and used during clinical decision-making and patient consultations.

What is the evidence for Neuroreader's accuracy and reliability in supporting clinical diagnoses?

Neuroreader has been validated in numerous studies, demonstrating high accuracy and reliability in quantifying brain atrophy compared to manual segmentation and other established methods. It provides objective data that can complement your clinical judgment in diagnosing and monitoring conditions like Alzheimer's disease.

Is Neuroreader compliant with relevant healthcare regulations and data privacy standards (e.g., HIPAA, GDPR)?

Yes, Neuroreader is designed with robust security features and adheres to strict data privacy regulations, including HIPAA and GDPR, to ensure patient data confidentiality and compliance. All data processing is handled with the highest standards of security and privacy.

What are the primary alternatives to Neuroreader for quantitative MRI analysis, and how does Neuroreader compare?

Alternatives include other quantitative MRI analysis software platforms and manual volumetric assessments. Neuroreader differentiates itself through its fully automated process, rapid analysis time, and comprehensive reporting, often providing a more efficient and standardized approach compared to manual methods or some less automated software.

What is the pricing model for Neuroreader, and are there different tiers or subscription options available for clinics of varying sizes?

Neuroreader typically offers flexible pricing models, which may include per-scan fees, subscription-based services, or institutional licenses, depending on the volume and specific needs of your clinic or hospital. It's best to contact the vendor directly for detailed pricing information tailored to your practice.

What are the limitations of Neuroreader, and in which clinical scenarios might its utility be reduced?

While highly accurate, Neuroreader's utility can be limited by the quality of the input MRI scan; artifacts or suboptimal sequences can affect results. It is a decision support tool and should always be used in conjunction with a comprehensive clinical evaluation and other diagnostic information, not as a standalone diagnostic.

What kind of training and technical support are provided to ensure effective use of Neuroreader in a clinical setting?

Comprehensive training and ongoing technical support are typically provided to ensure seamless integration and effective use of Neuroreader. This often includes online tutorials, user manuals, and direct support from the Neuroreader team to address any questions or technical issues.

Compare Neuroreader

Brainomix 360 e-CTA vs Neuroreader

Clinical Decision Support & Reference Adjacent · 65/100

Brainomix 360 e-CTA focuses on acute stroke patients, using CT angiography to detect large vessel occlusions and assess collaterals for immediate treatment decisions. Neuroreader, on the other hand,…